TY - JOUR T1 - Silymarin prevents diabetes-induced hyperpermeability in human retinal endothelial cells JO - Endocrinología, Diabetes y Nutrición (English ed.) T2 - AU - García-Ramírez,Marta AU - Turch,Mireia AU - Simó-Servat,Olga AU - Hernández,Cristina AU - Simó,Rafael SN - 25300180 M3 - 10.1016/j.endien.2018.03.010 DO - 10.1016/j.endien.2018.03.010 UR - https://www.elsevier.es/en-revista-endocrinologia-diabetes-nutricion-english-ed--413-articulo-silymarin-prevents-diabetes-induced-hyperpermeability-in-S2530018018300465 AB - IntroductionVascular endothelial growth factor (VEGF) plays an essential role in development of diabetic macular edema (DME). While there is evidence suggesting that silymarin, a flavonoid extracted from Silybum marianum, could be useful for prevention and treatment of diabetic nephropathy, no studies have been conducted in diabetic retinopathy (DR). The aim of this study was to assess the effect of silymarin on disruption of inner blood retinal barrier (BRB), the primary cause of DME. Materials and methodsHuman retinal endothelial cells (HRECs) were cultured under standard (5.5mM D-glucose) and diabetogenic conditions (25mM D-glucose and 25mM D-glucose + recombinant vascular endothelial growth factor [rVEGF, 25mg/mL]). To assess cell viability, three concentrations of silymarin were tested (2, 4 and 10μg/mL). The effect of silymarin on HREC disruption was determined using a dextran (70kD) permeability asssay. ResultsNo differences were found in the viability of HRECs treated with 2 or 4μg/mL of silymarin as compared to untreated cells, but viability significantly decreased after using 10μg/mL. The concentration of 4 μg/mL was therefore selected. Silymarin (4μg/mL) caused a significant decrease in VEGF-induced permeability in both media with 5.5nM (422±58 vs. 600±72 ng/mL/cm2; p<0.03) and 25nM of D-glucose (354 ± 28 vs. 567 ± 102 ng/mL/cm2; p<0.04). DiscussionOur results show that silymarin is effective for preventing hyperpermeability induced by diabetic conditions in HRECs. Further studies are needed to assess whether silymarin could be useful to treat DME. ER -